New hope for lymphoma patients with hepatitis b: maintenance drug aims to prevent relapse
NCT ID NCT07493109
First seen Mar 27, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study tests whether the drug chidamide can help keep diffuse large B-cell lymphoma (DLBCL) from coming back in patients who also have hepatitis B. Participants must have achieved complete remission after initial chemotherapy (R-CHOP). The trial will compare progression-free survival and overall survival in 200 adults receiving chidamide as maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.